Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“FLAMES Study”, NCT04169997) investigating the poly (ADP-ribose) polymerase (“PARP”) inhibitor, senaparib (product code: JS109/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (“IMPACT Therapeutics”), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (“FIGO”) stage III/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the “IDMC”) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.

Dr. Jianjun ZOU, President of Global Research and Development at Junshi Biosciences, commented on the positive results of the FLAMES study. 'As the first phase III clinical study of a domestically developed PARP inhibitor that has achieved positive results for advanced ovarian cancer maintenance treatment following first-line therapy, the FLAMES study’s interim analysis results show that senaparib can significantly extend the progression free survival (PFS) of patients with advanced ovarian cancer, regardless of the patient’s breast cancer susceptibility gene (BRCA) mutation status. We will collaborate with our partner IMPACT Therapeutics to engage in communication with regulatory agencies and look forward to expanding our commercial cancer drug portfolio to provide more effective treatment options at a lower cost for patients with advanced ovarian cancer.”

Ovarian cancer is one of the most commonly fatal malignant tumors affecting the female genital tract. According to GLOBOCAN 2020 data, around 310,000 new cases of ovarian cancer are diagnosed across the world annually, resulting in roughly 210,000 deaths every year. As the early symptoms of ovarian cancer are hidden and non-specific, around 80% of the patients with ovarian cancer are diagnosed at an advanced stage, with a five-year survival rate of only 40%. Although primary platinum-based chemotherapy can help alleviate ovarian cancer, most patients inevitably experience cancer relapse. Over the years, PARP inhibitor has revolutionized the treatment of ovarian cancer. In particular, PARP inhibitor maintenance treatment can extend the response time following first-line platinum-based chemotherapy and delay cancer relapse.

About the FLAMES Study

The FLAMES Study is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of senaparib as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved complete response (CR) or partial response (PR).

About Senaparib

As a novel targeted anti-tumor drug, senaparib is a PARP inhibitor. The clinical study of senaparib was supported by the national special project for innovative manufacturing of major new drugs under the 13th Five-Year Plan, and the inspection and acceptance procedures were completed smoothly. In August 2022, the fixed dose combination capsules of senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration.

In August 2020, Junshi Biosciences and IMPACT Therapeutics entered into a joint venture agreement to form a joint venture company. The joint venture company mainly engages in the research and development, and commercialization of small molecule anti-tumor drugs, including senaparib. IMPACT Therapeutics contributed the asset rights of senaparib within the joint venture territories of mainland China, Hong Kong and Macau Special Administrative Region. The Company and IMPACT Therapeutics each owns a 50% equity interest of the joint venture company.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800



Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

THỦ THUẬT HAY

Lộ diện Flipcover chính hãng của Nokia Lumia 930

Flipcover của Lumia 930 được thiết kế ấn tượng và có nhiều màu sắc cho người dùng lựa chọn.

Một số ứng dụng gọi taxi cho ngày mưa bão

Mai Linh là cái tên đã quá nổi tiếng trong ngành dịch vụ vận chuyển hành khách. Đây luôn là sự lựa chọn hàng đầu của người dùng mỗi khi có nhu cầu di chuyển bằng taxi. Có mặt không chỉ ở

Apple và các lỗi bảo mật từ bản cập nhật

Apple đã phát hành phần mềm mới cho iOS và macOS vượt xa các bản sửa lỗi nhỏ, các bản cập nhật đã vá một lỗ hổng bảo mật lớn có thể cho phép tin tặc có toàn quyền kiểm soát thiết bị của bạn.

Những tính năng nổi bật trong phiên bản iOS 16 sắp phát hành

Apple gần đây đã phát hành điện thoại dòng iPhone 14 mới và cũng thông báo rằng iOS 16 sẽ được ra mắt vào sáng sớm ngày 13 tháng 9. iOS 16 sẽ hỗ trợ iPhone 8, iPhone X hoặc các mẫu thiết bị mới hơn.

Hướng dẫn cách tra cứu thuế thu nhập cá nhân Online: Đơn giản hóa thủ tục nộp thuế

Việc thu thuế nhập cá nhân có thể gặp rất nhiều khó khăn và đặc biệt là với những người chưa có nhiều kinh nghiệm trong lĩnh vực này. Tuy nhiên, với sự phát triển của công nghệ thông tin, hiện tại bạn có thể tra cứu và

ĐÁNH GIÁ NHANH

Với 10 triệu trong tay, bạn chọn Galaxy A7 2017 hay "hốt ngay và luôn" Galaxy A8 2018

Galaxy A7 2017 có một thiết bị kết hợp kim loại và kính sang trọng. Phần lưng được bo cong dần ra phía cạnh viền, tạo cảm giá ôm tay nhất cho người dùng. Các chi tiết được hoàn thiện tỉ mỉ, với mình như thế là quá ổn

Đánh giá chi tiết Xperia XZs: Hoàn hảo quá liệu có ai mua?

Xperia XZs cho đến thời điểm hiện tại vẫn là thiết bị cao cấp nhất của Sony, cơ bản là Xperia XZ Premium vẫn chưa thấy tăm hơi đâu. Vậy hãy cùng...

Đánh giá chi tiết thiết kế và cấu hình của Sharp Aquos S3

Được nâng cấp lớn về thiết kế cho tương xứng hơn với giá, ngoại hình của Sharp Aquos S3 được thay thế chất liệu nhựa bằng kính cong 3D kết hợp cùng với khung kim loại, điều này làm cho chiếc máy sang trọng cứng cáp